FDA approves Valneva's Chikungunya vaccine for adults


Nov 10 (Reuters) - French drugmaker Valneva said on Friday the U.S. Food and Drug Administration (FDA) has approved its Chikungunya single-dose vaccine in individuals aged 18 and above.

The company said it plans to start selling the IXCHIQ vaccine in the U.S. early next year.

"Continued approval for this indication is contingent upon verification of clinical benefit in confirmatory studies", Valneva said.

(Reporting by Gaëlle Sheehan; Editing by Edmund Klamann)

((gaelle.sheehan@thomsonreuters.com; +48 58 7785110;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.